Boulé NG, Haddad E, Kenny GP, Wells GA, Sigal RJ Effects of exercise on glycemic control and body mass in type 2 diabetes mellitus: a meta-analysis of controlled clinical trials. JAMA. 2001 Sep 12;286(10):1218-27. Review.
Grossman E, Messerli FH, Goldbourt U High blood pressure and diabetes mellitus: are all antihypertensive drugs created equal? Arch Intern Med. 2000 Sep 11;160(16):2447-52. Review.
Haffner SM Insulin resistance, inflammation, and the prediabetic state. Am J Cardiol. 2003 Aug 18;92(4A):18J-26J. Review.
Hamdy O, Goodyear LJ, Horton ES Diet and exercise in type 2 diabetes mellitus. Endocrinol Metab Clin North Am. 2001 Dec;30(4):883-907. Review.
Hanley AJ, Williams K, Stern MP, Haffner SM Homeostasis model assessment of insulin resistance in relation to the incidence of cardiovascular disease: the San Antonio Heart Study. Diabetes Care. 2002 Jul;25(7):1177-84.
Helge JW Prolonged adaptation to fat-rich diet and training; effects on body fat stores and insulin resistance in man. Int J Obes Relat Metab Disord. 2002 Aug;26(8):1118-24.
Honkola A, Forsén T, Eriksson J Resistance training improves the metabolic profile in individuals with type 2 diabetes. Acta Diabetol. 1997 Dec;34(4):245-8.
Kelley DE, Goodpaster BH Effects of exercise on glucose homeostasis in Type 2 diabetes mellitus. Med Sci Sports Exerc. 2001 Jun;33(6 Suppl):S495-501; discussion S528-9. Review.
Kelley GA, Kelley KA, Tran ZV Aerobic exercise and resting blood pressure: a meta-analytic review of randomized, controlled trials. Prev Cardiol. 2001 Spring;4(2):73-80.
Kohl HW 3rd, Dunn AL, Marcus BH, Blair SN A randomized trial of physical activity interventions: design and baseline data from project active. Med Sci Sports Exerc. 1998 Feb;30(2):275-83.
Leon AS, Sanchez OA Response of blood lipids to exercise training alone or combined with dietary intervention. Med Sci Sports Exerc. 2001 Jun;33(6 Suppl):S502-15; discussion S528-9. Review.
Nelson KM, Reiber G, Boyko EJ; NHANES III Diet and exercise among adults with type 2 diabetes: findings from the third national health and nutrition examination survey (NHANES III). Diabetes Care. 2002 Oct;25(10):1722-8.
Ridker PM, Hennekens CH, Buring JE, Rifai N C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000 Mar 23;342(12):836-43.
Ridker PM High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation. 2001 Apr 3;103(13):1813-8.
Snyder KA, Donnelly JE, Jabobsen DJ, Hertner G, Jakicic JM The effects of long-term, moderate intensity, intermittent exercise on aerobic capacity, body composition, blood lipids, insulin and glucose in overweight females. Int J Obes Relat Metab Disord. 1997 Dec;21(12):1180-9.
Stewart KJ Exercise training and the cardiovascular consequences of type 2 diabetes and hypertension: plausible mechanisms for improving cardiovascular health. JAMA. 2002 Oct 2;288(13):1622-31. Review.
Taylor PA, Ward A Women, high-density lipoprotein cholesterol, and exercise. Arch Intern Med. 1993 May 24;153(10):1178-84. Review.
Willey KA, Singh MA Battling insulin resistance in elderly obese people with type 2 diabetes: bring on the heavy weights. Diabetes Care. 2003 May;26(5):1580-8. Review.
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.